IQVIA Healthcare-grade AI®

Leading the Way

Accelerating decision making and deployment with trusted Healthcare-grade AI[®] applications.

Contributing to trustworthy and defensible AI guidelines to meet stakeholder needs

IQVIA Healthcare-grade AI[®] ensures generative AI is harnessed responsibly and with the speed, precision, and trust required for the healthcare industry.

The information below explores how trustworthy, defensible AI provides industry confidence in the quality and accuracy of generative AI in healthcare. We also present a case study that illustrates how AI capabilities and a comprehensive end-to-end workflow support emerging market needs.

Determining the path forward

Life sciences and healthcare organizations have specific needs that raise important questions about the use of generative AI in guiding decision making. Emerging regulatory oversight and expectations in how AI systems will be managed heightens the risk profile of novel uses and applications for generative AI. Unclear governance through principles-based guidance for generative AI adds uncertainty regarding expectations and risks. A lack of clarity around this guidance can make it challenging for stakeholders about a clear path forward, ultimately slowing decision making.

Moving forward through collaboration

IQVIA collaborates with healthcare, technology and regulatory organizations globally to responsibly accelerate the evolution and adoption of AI in healthcare and improve patient outcomes. We have informed 25+ guidelines represented in regulatory guidance and standards worldwide (e.g., ISO, UK ICO).

IQVIA Healthcare-grade AI[®] implements the following guidelines to reduce confusion around expectations and risks of using generative AI for decision making and ensure stakeholder needs are met:

- Enabling data for good with an actionable framework to evaluate the uses of AI and when different tiers of governance are needed to build a trusted system.
- Adhering to regulations and user expectations across jurisdictions with formal assessment against international standards in the management of AI.
- Developing a pragmatic implementation framework that provides a roadmap for greater transparency with clear and actionable methods to improve safe AI efficiency.

Life sciences and healthcare organizations have specific needs that raise important questions about the use of generative AI in guiding decision making.

Gaining momentum through alignment


Implementing clear guidelines to satisfy regulator expectations and internal needs for driving business outcomes answers stakeholder questions about the safe use and efficacy of generative AI in healthcare. Improved stakeholder alignment across various functional teams regarding expectations and the path forward help accelerate decision making.

IQVIA is recognized as the leader in generative AI expertise for RWE and Medical Affairs solutions

Source: As determined by independent research on RWE/Medical Affairs Market landscape

Figure 1: Defensible Data and AI — Driving trustworthy patient insights at scale

Solutions and services informed by expertise in technology, data protection, and privacy to provide world-class guidance and solutions on safe uses of predictive and generative AI, part of IQVIA Applied AI Science



Source: IQVIA Applied AI Science.

Notes: For more information, please contact defensibleAI@iqvia.com or visit http://iqvia.com/defensible-AI

Case study: IQVIA Healthcare-grade AI[®] optimizes client research monitoring for COVID-19

Delivering a living review literature database for a Top 10 pharma client

Situation

The volume and velocity of published research related to COVID-19 is unprecedented in its scale and diversity. The ongoing extraction of insights from such a rich and expansive amount of information posed a significant challenge for a Top 10 Pharma client seeking enhanced publication monitoring with efficient selection and accurate extraction from the most relevant and high-quality peer-reviewed articles.

The ongoing extraction of insights from such a rich and expansive amount of information posed a significant challenge.


Solution

The capabilities of IQVIA Healthcare-grade AI[®] enabled a "living review" database in which key publications were continuously searched and selected for review and real world data extracted from the literature, giving the client increased insight into the desired research. To expedite the literature review process, generative AI and Natural Language Processing (NLP) methods were combined with IQVIA Evidence Synthesis expertise to automate data curation, extraction and synthesis. Our Human Assisted Review Tool (HART) interface ensured prompt validation of results with expert oversight to ensure accuracy.

Strategic planning for future AI,

identifying emerging technologies

Continued on the next page...



Source: IQVIA Applied AI Science.

Results

The advanced search and extraction capabilities of the living review delivered significant results for the client, including a 70% reduction in manual data extraction efforts. Adapting methods based on IQVIA expert feedback from HART allowed for seamless integration between experts and AI, delivering capabilities precisely optimized for the client's needs.

6

17 Studies – Sort 🛩	Age and Sex Following C	-specific Risks OVID-19 Messe	of Myocard	itis and P accines	ericarditis
v Verstal. An 2046, 2022)	UPD476D 25 JUAK 2102				
erletael et al. Igr 2001, 2022)	Lead Author: Le Vu, Stephan Sponsor(x): Not Reported	e. Chatlen: Not Commun. 2022 Ju	n 26(13)(1):3633. (COT 1	0.1038/541467-022-314	11-5
lock et al. lyr tim, 2022)					
terrenanti et el. en 2009, 2022	Objectives, Design	Primary Endpoints and	Inclusion and Exclusion		Conclusions and
0ar et al. ar 2001, 2022)	and Size	Definitions Criter		Results	Limitations
i et el. et 25et, 2022		ying publication includes data reli own. The article can be accessed to		accines, however only d	irta and information
utility at al. Inc. (MAY, 2021)					
norm, et al. ec.1405,2021)	😑 1-7 Deys efter Dose 1	🛚 8-21 Døys øfter Dose 1 🛛 🖷 1-	7 Deys efter Dose 2 🛛 🖷 8-2	1 Days after Dose 2	Dutaset
euchara et al. ec.346,2021)	Adverted Adder Barlo	of Myocarditis with Ex	norus to milita Va	ricer Within 1	Orient Original
rahmand at al. Iou 20m, 2021)	to 7 Days and 8 to 21		posure to mRNA va	cones within 1	O By Age and Sex
100 mig. et al. 100 mig. 2021)					Patients with a Hittory of SARS- Call 2 Infection
terminet at al. Include, 2021)	1-7 Days after Dose 1				Filters
none et al. Io: Ath, 2021)	84714242	-	н	1.8(1.3 w 2.5)	Outcome(s)
ain an al ap 3-4, 2021)					S Mysoardina S Pericardina
104-15 al. vg 2545, 20210	8-21 Days after Dass 1				Vaccinated
	8474242			12(0.0210-14)	S INTERN
					Variantial
	5-7 Days after Date 2				Aprilation
5-15-4710 3					

ies for v	Safety an Vaccine	nd Effica	cy of a Th	ird Dose	of BNT16	2b2 COVID-1			
n	UPDATED 23 MARCH 2	1622							
e el el 19. 2021) el el 1. 2021)		Lead Author: Monrie, Educe, Oladies: Witryly Hed. 2022 Mar 23							
4 (121) (121)	Objectives. Design and Size	Baseline Demographics	Primary Endpoints and Definitions	Inclusion and Exclusion Criteria	Results	Additional Conduct Results United			
n d h, 2020		The vaccine efficacy reported was as observed in the clinical trials. Vaccine efficacy is expected to networkly wane over time and may also impacted by the emergence of new variance.							
		Participants without Evidence of Previous Infection Outer							
		Participal	ints without Evidence	of Previous Infection		Outcomes			
-6.478				of Previous Infection not of Previous Infection	un.	Outcomes Vectore Efficacy			
4.418		 Perticipants te Efficacy Aga 	with or without Evide		≥ 7 Days After	Vaccine Efficacy Vaccine Safety			
4.44		 Perticipants te Efficacy Aga 	with or without Evide	-19 Occurrence	≥ 7 Days After	Vaccine Efficacy Vaccine Safety			
4.01	Dose 3, by Evic	Fertilipens Efficacy Aga dence of Prev	with or without Evide	-19 Occurrence - 7 Days After 0	≥ 7 Days After Dose 3	Vaccine Efficany Vaccine Sefety Consultation Social Vaccine Sefety Symptome October			
441	Dose 3, by Evic	Fertilipens Efficacy Aga dence of Prev	with or without Evide	-19 Occurrence - 7 Days After 0	≥ 7 Days After	Vaccine Efficany Vaccine Sefety Consultation Social Vaccine Sefety Symptome October			
449	Dose 3, by Evic	Fertilipens Efficacy Aga dence of Prev	with or without Evide	-19 Occurrence - 7 Days After 0	≥ 7 Days After Dose 3	Vacans Muay Vacans Sifkay Canadaria Inida Vacans Sifkay Spreases Dataset © Social O Signaria			
	Dose 3, by Evic	Participants Efficacy Aga dence of Prev	with or without Evide	-19 Occurrence - 7 Days After 0	≥ 7 Days After Dose 3	Vaccine Efficany Vaccine Setty Consulation Setty Vaccine Setty Symptome Settemet © Overall			
4.478	Dose 3, by Evic	Participants Efficacy Aga dence of Prev	with or without Evide	ice of Previous Infecti -19 Occurrence < 7 Days After 0	≥ 7 Days After Dose 3	Vacion Sharp Vacion Sinfor Considere Sinfor Syngerson Dataset © Denal Sinforma Consensity Filters			
14.473	Dose 3, by Evic	Participants Efficacy Aga dence of Prev	with or without Evide	ice of Previous Infecti -19 Occurrence < 7 Days After 0	≥ 7 Days After Dose 3 ● 1 %3 (015 to 96.3)	Vectors SPLags Vactors Softery Considentia Indete Vactors Softery Spreasons Dataset © Donall Softery Softery Consolit			



IQVIA Healthcare-grade AI® is AI engineered to meet the level of precision, speed, and trust required in life sciences and healthcare. Learn more.





CONTACT US iqvia.com

Writing

ihil

Research

Databases